Clinical Trial

From the Emergency Department Directly to Ablation of Atrial Fibrillation Study

Study acronym: EMERGE-Cryo
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The study is a prospective, two-arm, randomized, open-label, blinded endpoint, multi-center study to investigate the impact of first line ablation in patients presenting at the emergency room with recent-onset paroxysmal or persistent atrial fibrillation.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-03-23; most recent amendment 2026-05-20.
Status change: Recruiting → Active, Not Recruiting 2026-04-28
Trial Details
NCT Number NCT05294445
Lead Sponsor Asklepios proresearch
Collaborators: Atrial Fibrillation Network, Medtronic Bakken Research
Conditions Atrial Fibrillation (AF)
Enrollment 350 participants
Start Date 2021-12-15
Primary Completion 2026-12-14 (estimated)
Study Completion 2028-12-14 (estimated)
Updated on ClinicalTrials.gov 2026-05-22